January 16, 2026 · Form 4 insider transaction
Uihlein Richard E bought 13,158 shares of Galectin Therapeutics Inc. at $3.04 per share, a transaction worth $40.0K. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 5 days after the transaction.
These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $40,000 for 2026. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2026.